Suppr超能文献

未处理的对照和阳性对照(己烯雌酚二磷酸酯,2.5微克/千克,每日两次)Wistar和Sprague-Dawley大鼠子宫营养反应试验(一种体内雌激素反应试验)中的变异性。

Variability in the uterotrophic response assay (an in vivo estrogenic response assay) in untreated control and positive control (DES-DP, 2.5 microG/kg, bid) Wistar and Sprague-Dawley rats.

作者信息

Christian M S, Hoberman A M, Bachmann S, Hellwig J

机构信息

Argus International, Inc., Horsham, PA 19044, USA.

出版信息

Drug Chem Toxicol. 1998;21 Suppl 1:51-100. doi: 10.3109/01480549809007404.

Abstract

Inclusion of biological outlier values was found to bias the results of rat uterotrophic assays towards false negatives, i.e., not identify uterotrophic effects in treated populations. The present investigation was conducted to identify the background variability in the rat uterotrophic assay and to evaluate the need to exclude biological outlier values in untreated control groups. The Styrene Steering Committee (SSC) of the European Chemical Industry Council (CEFIC) co-sponsored this work with Argus Research Laboratories (Argus). The rat uterotrophic response assay originally was used as a pharmacology screen to identify estrogenic agents. Classically, 5 to 10 immature female rats (18 to 22 days of age) are administered an agent for three or four days. At sacrifice on the following day (21 to 26 days of age), the uterus is removed, weighed and a uterine weight/terminal body weight ratio calculated. This in vivo assay has been adapted for use in identifying the potential estrogenicity of chemicals, generally using 10 immature female rats per group, more closely controlling the ages, and adding one or more positive control groups to demonstrate sensitivity and response of the test system. Statistically significant increases in the positive control group means for absolute and relative uterine weights, as compared with the untreated (or vehicle-treated) means, is generally interpreted as identifying a sensitive test system. The untreated (and/or vehicle-treated) control group is then compared with the various test groups, and statistically significant increases in the mean absolute and relative uterine weights are identified as evidence of estrogenicity of the agent. Although not fully described previously, the inherent biological variability existing in both untreated and treated animals, can confound interpretation of the data, especially when numbers are relatively small. Our laboratories have identified that under controlled GLP-compliant conditions, some Wistar rats [randomly assigned (weight-ordered) to groups of ten at 22 +/- 1 days of age, and sacrificed when 26 +/- 1 days of age] in untreated control groups have high relative uterine weights that skew data distributions such that statistically significant differences are not present between untreated control and positive control groups. Based on these observations, further evaluations of untreated control and positive control (DES-DP, 2.5 micrograms/kg, b.i.d.) populations of three rat strains [Wistar--Chbb:THOM-SPF, Wistar--Crl:(WI)BR and Sprague-Dawley--Crl:CD(SD)IBS BR VAF/Plus "International Genetic Standard"] were made to define when such normal findings should be considered biological outliers, and whether outlier values should be excluded from analyses. Our data indicate that body weight is not always predictive of uterine weight, that relative uterine weight outlier values occur in each of these rat strains, and that statistically significant differences exist between groups of untreated control animals when outlier values are included in analyses. Of 98, 60 and 60 untreated control rats in the three respective strains, 11 (11.2%), 16 (26.7%) and 15 (25.0%) had relative uterine weights > or = 0.150%, and 5 (5.1%), 4 (6.7%) and 9 (15.0%) of these rats had relative uterine weights > or = 0.200%, values within the positive control range. All positive control rats attained relative uterine weights > or = 0.100%. Of 50, 60 and 60 positive control rats in the three respective rat strains, 27 (54%), 47 (78.3%) and 36 (60%) had relative uterine weights > or = 0.200%, 9 (18%), 2 (3.3%) and 7 (11.7%) had relative uterine weights > or = 0.300% and 5 (10%), 1 (1.7%) and 3 (5%) had relative uterine weights > or = 0.400%. The incidences of relative uterine weights > or = 0.300% in the positive control group may indicate the presence of high responders. Histological evaluations of uteri of positive control rats and untreated control rats with relative uterine weights > or = 0.

摘要

发现纳入生物学异常值会使大鼠子宫增重试验结果偏向假阴性,即无法识别受试群体中的子宫增重效应。本研究旨在确定大鼠子宫增重试验中的背景变异性,并评估是否需要排除未处理对照组中的生物学异常值。欧洲化学工业理事会(CEFIC)的苯乙烯指导委员会(SSC)与阿格斯研究实验室(Argus)共同赞助了这项工作。大鼠子宫增重反应试验最初用作药理学筛选以识别雌激素类药物。传统上,给5至10只未成熟雌性大鼠(18至22日龄)给药三或四天。在次日(21至26日龄)处死后,取出子宫称重并计算子宫重量/终末体重比。这种体内试验已适用于识别化学物质的潜在雌激素活性,通常每组使用10只未成熟雌性大鼠,更严格地控制年龄,并添加一个或多个阳性对照组以证明测试系统的敏感性和反应性。与未处理(或赋形剂处理)的平均值相比,阳性对照组绝对和相对子宫重量的平均值有统计学显著增加,通常被解释为测试系统敏感。然后将未处理(和/或赋形剂处理)的对照组与各个测试组进行比较,绝对和相对子宫重量平均值的统计学显著增加被确定为该药物具有雌激素活性的证据。尽管之前没有完整描述,但未处理和处理动物中存在的固有生物学变异性可能会混淆数据的解释,尤其是当样本数量相对较少时。我们实验室已确定,在符合GLP的受控条件下,一些未处理对照组中的Wistar大鼠[在22±1日龄时随机分配(按体重排序)为每组10只,并在26±1日龄时处死]具有较高的相对子宫重量,这会使数据分布发生偏斜,以至于未处理对照组和阳性对照组之间不存在统计学显著差异。基于这些观察结果,对三种大鼠品系[Wistar - Chbb:THOM - SPF、Wistar - Crl:(WI)BR和Sprague - Dawley - Crl:CD(SD)IBS BR VAF/Plus“国际遗传标准”]的未处理对照组和阳性对照组(己烯雌酚二磷酸酯,2.5微克/千克,每日两次)群体进行了进一步评估,以确定何时应将此类正常发现视为生物学异常值,以及是否应从分析中排除异常值。我们的数据表明体重并不总是子宫重量的预测指标,这些大鼠品系中的每一个都出现了相对子宫重量异常值,并且当分析中包含异常值时,未处理对照动物组之间存在统计学显著差异。在三个相应品系的98只、60只和60只未处理对照大鼠中,分别有11只(11.2%)、16只(26.7%)和15只(25.0%)的相对子宫重量≥0.150%,其中这些大鼠中有5只(5.1%)、4只(6.7%)和9只(15.0%)的相对子宫重量≥0.200%,这些值在阳性对照范围内。所有阳性对照大鼠的相对子宫重量≥0.100%。在三个相应大鼠品系的50只、60只和60只阳性对照大鼠中,分别有27只(54%)、47只(78.3%)和36只(60%)的相对子宫重量≥0.200%,9只(18%)、2只(3.3%)和7只(11.7%)的相对子宫重量≥0.300%,5只(10%)、1只(1.7%)和3只(5%)的相对子宫重量≥0.400%。阳性对照组中相对子宫重量≥0.300%的发生率可能表明存在高反应者。对相对子宫重量≥0. 的阳性对照大鼠和未处理对照大鼠的子宫进行组织学评估。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验